Research programme: small molecule therapeutics - Starpharma

Drug Profile

Research programme: small molecule therapeutics - Starpharma

Alternative Names: Dendrimer-cisplatin; Dendrimer-gemcitabine; Dendrimer-methotrexate; Dendrimer-paclitaxel; Dendrimer-testosterone; SPL-7435; SPL-7484

Latest Information Update: 28 Jan 2014

Price : $50

At a glance

  • Originator Starpharma
  • Class Androstenols; Dendrimers; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; DNA cross linking agents; DNA synthesis inhibitors; Mitosis inhibitors; Tubulin polymerisation inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jan 2014 This programme is still in active development
  • 19 Dec 2011 Starpharma and Eli Lilly expand their collaboration; preclinical development is ongoing
  • 30 Jun 2010 Starpharma and Monash University collaboration receives $AUS420 000 grant from Australian Research Council for the development dendrimers-based drug delivery for use in cancer, HIV and lymphatic indications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top